Recent progress in the understanding of relaxin family peptides and their receptors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Long-acting relaxin analogues: a novel tool in cardiology.Frontiers in pharmacology · 2025
   Review
2. Immunoexpression of Relaxin and Its Receptors in Stifle Joints of Dogs with Cranial Cruciate Ligament Disease.Animals : an open access journal from MDPI · 2022
   Article
3. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy.Nature communications · 2019
   Article
4. Multi-Component Mechanism of H2 Relaxin Binding to RXFP1 through NanoBRET Kinetic Analysis.iScience · 2019
   Article
5. Relaxin influences ileal muscular activity through a dual signaling pathway in mice.World journal of gastroenterology · 2018
   Article
6. Recent progress in the understanding of relaxin family peptides and their receptors.British journal of pharmacology · 2017
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as